Rationale and design of the DARWIN-T2D (DApagliflozin Real World evIdeNce in Type 2 Diabetes) A multicenter retrospective nationwide Italian study and crowdsourcing opportunity

被引:25
作者
Fadini, G. P. [1 ]
Zatti, G. [1 ]
Consoli, A. [2 ]
Bonora, E. [3 ]
Sesti, G. [4 ]
Avogaro, A. [1 ]
机构
[1] Univ Padua, Dept Med, I-35128 Padua, Italy
[2] Univ G dAnnunzio, Dept Med & Aging Sci, I-68100 Chieti, Italy
[3] Univ Verona, Dept Med, I-37154 Verona, Italy
[4] Magna Graecia Univ Catanzaro, Dept Med & Surg Sci, I-88100 Catanzaro, Italy
关键词
Randomized controlled trial; Retrospective study; Sodium glucose co-transporter-2 inhibitor; Real-life; GLUCOSE-LOWERING DRUGS; ALL-CAUSE MORTALITY; GLYCEMIC CONTROL; BLOOD-PRESSURE; BODY-WEIGHT; LOWER RISK; FAT MASS; THERAPY; METFORMIN; MELLITUS;
D O I
10.1016/j.numecd.2017.08.001
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Randomized controlled trials (RCTs) in the field of diabetes have limitations inherent to the fact that design, setting, and patient characteristics may be poorly transferrable to clinical practice. Thus, evidence from studies using routinely accumulated clinical data are increasingly valued. Aims: We herein describe rationale and design of the DARWIN-T2D (DApagliflozin RealWorld evIdeNce in Type 2 Diabetes), a multicenter retrospective nationwide study conducted at 50 specialist outpatient clinics in Italy and promoted by the Italian Diabetes Society. Data synthesis: The primary objective of the study is to describe the baseline clinical characteristics (particularly HbA1c) of patients initiated on dapagliflozin from marketing authorization approval to the end of 2016. Secondary and exploratory objectives will evaluate the changes in glycaemic and extraglycaemic efficacy parameters after initiation of dapagliflozin or after initiation of comparator glucose lowering medications (DPP-4 inhibitors, gliclazide extended release, and long-acting GLP-1 receptor agonists). An automated software will extract relevant data from the same electronic chart system at all centres, thereby minimizing data treatment and human intervention. Conclusion: The study is expected to collect an enormous dataset of information on dapagliflozin- and comparator-using patients. After study completion, the Italian Diabetes Society will launch an open crowdsourcing call on the DARWIN-T2D database, challenging diabetes researchers to apply their ideas and approaches to address new unmet needs and knowledge gaps in diabetes. We believe this will move DARWIN-T2D to the next generation of real world studies. (c) 2017 The Italian Society of Diabetology, the Italian Society for the Study of Atherosclerosis, the Italian Society of Human Nutrition, and the Department of Clinical Medicine and Surgery, Federico II University. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:1089 / 1097
页数:9
相关论文
共 33 条
[1]   Role of Sodium-Glucose Cotransporter 2 (SGLT 2) Inhibitors in the Treatment of Type 2 Diabetes [J].
Abdul-Ghani, Muhammad A. ;
Norton, Luke ;
DeFronzo, Ralph A. .
ENDOCRINE REVIEWS, 2011, 32 (04) :515-531
[2]   Hypoglycaemia when adding sulphonylurea to metformin: a systematic review and network meta-analysis [J].
Andersen, Stig Ejdrup ;
Christensen, Mikkel .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2016, 82 (05) :1291-1302
[3]  
ARNO Diabetes, 2015, PROF ASS POP CON DIA
[4]   Continued efforts to translate diabetes cardiovascular outcome trials into clinical practice [J].
Avogaro, Angelo ;
Fadini, Gian Paolo ;
Sesti, Giorgio ;
Bonora, Enzo ;
Del Prato, Stefano .
CARDIOVASCULAR DIABETOLOGY, 2016, 15
[5]   Dapagliflozin in patients with type II diabetes mellitus, with and without elevated triglyceride and reduced high-density lipoprotein cholesterol levels [J].
Bays, Harold E. ;
Sartipy, Peter ;
Xu, John ;
Sjostrom, Carl David ;
Underberg, James A. .
JOURNAL OF CLINICAL LIPIDOLOGY, 2017, 11 (02) :450-458
[6]   Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin [J].
Bolinder, J. ;
Ljunggren, O. ;
Johansson, L. ;
Wilding, J. ;
Langkilde, A. M. ;
Sjostrom, C. D. ;
Sugg, J. ;
Parikh, S. .
DIABETES OBESITY & METABOLISM, 2014, 16 (02) :159-169
[7]   Effects of Dapagliflozin on Body Weight, Total Fat Mass, and Regional Adipose Tissue Distribution in Patients with Type 2 Diabetes Mellitus with Inadequate Glycemic Control on Metformin [J].
Bolinder, Jan ;
Ljunggren, Osten ;
Kullberg, Joel ;
Johansson, Lars ;
Wilding, John ;
Langkilde, Anna Maria ;
Sugg, Jennifer ;
Parikh, Shamik .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2012, 97 (03) :1020-1031
[8]   Learning What We Didn't Know - The SPRINT Data Analysis Challenge [J].
Burns, Nancy S. ;
Miller, Pamela W. .
NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (23) :2205-2207
[9]   Long-term glycaemic response and tolerability of dapagliflozin versus a sulphonylurea as add-on therapy to metformin in patients with type 2 diabetes: 4-year data [J].
Del Prato, S. ;
Nauck, M. ;
Duran-Garcia, S. ;
Maffei, L. ;
Rohwedder, K. ;
Theuerkauf, A. ;
Parikh, S. .
DIABETES OBESITY & METABOLISM, 2015, 17 (06) :581-590
[10]   Effects of the SGLT2 inhibitor dapagliflozin on HDL cholesterol, particle size, and cholesterol efflux capacity in patients with type 2 diabetes: a randomized placebo-controlled trial [J].
Fadini, Gian Paolo ;
Bonora, Benedetta Maria ;
Zatti, Giancarlo ;
Vitturi, Nicola ;
Iori, Elisabetta ;
Marescotti, Maria Cristina ;
Albiero, Mattia ;
Avogaro, Angelo .
CARDIOVASCULAR DIABETOLOGY, 2017, 16